Biosilicified oncolytic adenovirus for cancer viral gene therapy
Source abstract
Abstract
Oncolytic adenoviruses (OAs) have shown great potential for cancer viral gene therapy in clinical studies. To date, clinical trials have shown that the curative efficacy of OAs is still limited by hepatic sequestration and preexisting neutralizing antibodies (nAbs), which decrease the accumulation of the OAs in tumors. Herein, with the biosilicification method, we encapsulated an OA encoding the anticancer gene Trail (OA-Trail) with silica, which significantly improved virus distribution and tumor inhibition. In vitro and in vivo results indicated that compared with the native OA, biosilicified OA-Trail (OA-Trail@SiO2) showed significantly reduced viral clearance in the liver and evaded nAb degradation, inducing an efficacious anticancer effect under the premise of biocompatibility. These achievements present an alternative strategy involving biosilicification for enhanced OA-based cancer gene therapy.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Virus-based gene therapy research · Cancer Research and Treatments · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
School of Materials Science and Engineering
Zhejiang Sci-Tech University
Hangzhou 310018
China
Zhejiang-Mauritius Joint Research Center for Biomaterials and Tissue Engineering
Research Center for Clinical Pharmacy & Key Laboratory for Drug Evaluation and Clinical Research of Zhejiang Province
The First Affiliated Hospital
Zhejiang University School of Medicine
Hangzhou 310003
State Key Laboratory of Cell Biology
Institute of Biochemistry and Cell Biology
Shanghai Institutes for Biological Sciences
Chinese Academy of Sciences
Shanghai 200031
Funding
National Natural Science Foundation of China · Natural Science Foundation of Zhejiang Province · Department of Education of Zhejiang Province
References (40)
Show source-provided references
1. Luigi · Nature · 2015 · 526 · 35110.1038/nature15818 ↗
2. Elie · Nat. Rev. Drug Discovery · 2015 · 14 · 36910.1038/nrd4643 ↗
3. Waddington · Cell · 2008 · 132 · 39710.1016/j.cell.2008.01.016 ↗
4. Padilla · Mol. Ther. · 2016 · 24 · 610.1038/mt.2015.194 ↗
5. Roberts · Nature · 2006 · 441 · 23910.1038/nature04721 ↗
6. Xu · Mol. Ther. · 2014 · 22 · 150410.1038/mt.2014.80 ↗
7. Draganov · J. Transl. Med. · 2019 · 17 · 10010.1186/s12967-019-1829-z ↗
8. Qiao · Biomater. Sci. · 2020 · 8 · 247210.1039/D0BM00172D ↗
9. Kim · J. Controlled Release · 2010 · 148 · e10010.1016/j.jconrel.2010.07.074 ↗
10. Park · J. Controlled Release · 2010 · 142 · 23810.1016/j.jconrel.2009.11.001 ↗
11. Fisher · Adv. Drug Delivery Rev. · 2010 · 62 · 24010.1016/j.addr.2009.12.003 ↗
12. Yilmazer · Biomaterials · 2013 · 34 · 135410.1016/j.biomaterials.2012.10.053 ↗
13. Kim · Biomaterials · 2012 · 33 · 183810.1016/j.biomaterials.2011.11.020 ↗
14. Singh · ACS Nano · 2008 · 2 · 104010.1021/nn8000565 ↗
15. Rechamalla · Nanotoxicology · 2019 · 13 · 116110.1080/17435390.2019.1643049 ↗
16. Jones · ACS Nano · 2012 · 6 · 990010.1021/nn303472r ↗
17. Yao · Adv. Mater. · 2017 · 29 · 160590310.1002/adma.201605903 ↗
18. Wang · Angew. Chem., Int. Ed. · 2012 · 51 · 1057610.1002/anie.201206154 ↗
19. Wang · Adv. Healthcare Mater. · 2012 · 1 · 44310.1002/adhm.201200034 ↗
20. Wang · Adv. Mater. · 2016 · 28 · 69410.1002/adma.201503740 ↗
21. Chen · ACS Nano · 2016 · 10 · 1154810.1021/acsnano.6b06182 ↗
22. Wang · ACS Nano · 2015 · 9 · 79910.1021/nn5063276 ↗
23. Wang · Chem. Sci. · 2016 · 7 · 175310.1039/C5SC03847B ↗
24. Sapre · J. Controlled Release · 2019 · 297 · 4810.1016/j.jconrel.2019.01.034 ↗
25. Stöber · J. Colloid Interface Sci. · 1968 · 26 · 6210.1016/0021-9797(68)90272-5 ↗
26. Nassif · Nat. Mater. · 2002 · 1 · 4210.1038/nmat709 ↗
27. Avnir · Chem. Mater. · 1994 · 6 · 160510.1021/cm00046a008 ↗
28. Finnie · J. Mater. Chem. · 2000 · 10 · 109910.1039/a909350h ↗
29. Neville · Langmuir · 2013 · 29 · 1468110.1021/la403040u ↗
30. Sumper · Angew. Chem., Int. Ed. · 2003 · 42 · 519210.1002/anie.200352212 ↗
31. Sun · Acta Biomater. · 2019 · 97 · 9310.1016/j.actbio.2019.06.059 ↗
32. Nayab · ACS Appl. Mater. Interfaces · 2014 · 6 · 440810.1021/am500123k ↗
33. O'Shea · Cancer Cell · 2004 · 6 · 61110.1016/j.ccr.2004.11.012 ↗
34. Ashkenazi · Science · 1998 · 281 · 130510.1126/science.281.5381.1305 ↗
35. Shinoura · Cancer Res. · 1999 · 59 · 3411
36. Medina-Kauwe · Adv. Drug Delivery Rev. · 2003 · 55 · 148510.1016/j.addr.2003.07.010 ↗
37. Rad · ACS Appl. Mater. Interfaces · 2019 · 11 · 1050510.1021/acsami.8b21609 ↗
38. Gafur · Biomater. Sci. · 2019 · 7 · 358110.1039/C9BM00724E ↗
39. Doronin · Science · 2012 · 338 · 79510.1126/science.1226625 ↗
40. Quintanilla · J. Clin. Invest. · 2019 · 129 · 140710.1172/JCI122287 ↗